HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immune Mediated Cerebellar Ataxia: An Unknown Manifestation of Graft-versus-Host Disease.

Abstract
Neurologic complications of allogeneic hematopoietic cell transplantation (allo-HCT) include infections, cerebrovascular events, therapy-induced neurotoxicity, recurrent malignancies, and neurologic manifestations of graft-versus-host disease (GVHD). Anti-glutamic acid decarboxylase (GAD) antibody-associated cerebellar ataxia is a well-established disorder of autoimmune origin, but there are no reports in the literature of its occurrence following allo-HCT. We describe a middle-aged woman with chronic GVHD after allo-HCT who presented with a rapidly progressive cerebellar syndrome. Thorough investigation revealed only cerebellar atrophy on brain imaging and positive anti-GAD65 antibodies in serum and cerebrospinal fluid suggesting the diagnosis of anti-GAD antibody-associated cerebellar ataxia. Despite prompt treatment with high-dose corticosteroids, intravenous immunoglobulins, and rituximab, the patient's condition rapidly deteriorated, and she died 4 months later. This case suggests that anti-GAD antibody-associated cerebellar ataxia may be a rare manifestation of chronic GVHD.
AuthorsLiat Shargian-Alon, Pia Raanani, Uri Rozovski, Tali Siegal, Shlomit Yust-Katz, Moshe Yeshurun
JournalActa haematologica (Acta Haematol) Vol. 141 Issue 1 Pg. 19-22 ( 2019) ISSN: 1421-9662 [Electronic] Switzerland
PMID30439710 (Publication Type: Case Reports, Journal Article)
Copyright© 2018 S. Karger AG, Basel.
Chemical References
  • Antineoplastic Agents, Immunological
  • Autoantibodies
  • Immunoglobulins, Intravenous
  • Rituximab
Topics
  • Antineoplastic Agents, Immunological (therapeutic use)
  • Autoantibodies (blood)
  • Cerebellar Ataxia (complications, diagnosis, drug therapy)
  • Female
  • Graft vs Host Disease (diagnosis, etiology)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Immunoglobulins, Intravenous
  • Leukemia, Myeloid (therapy)
  • Middle Aged
  • Rituximab (therapeutic use)
  • Transplantation, Homologous (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: